Référentiel des médicaments
Pamidronate
Pamidronate is a medicine in the class musculoskeletal. It is used for hypercalcemia of malignancy.
- Classe médicamenteuse: Musculoskeletal
- Indications: hypercalcemia of malignancy
Dernière mise à jour
Réservé aux professionnels de santé — à titre de référence uniquement. Cette page est un bref résumé, pas un avis médical, et ne remplace ni la notice officielle ni le jugement clinique. Vérifiez toujours avant de prescrire ou de délivrer.
Le contenu clinique de cette page n'est disponible qu'en anglais.
L'essentiel
- Classe médicamenteuse
- Musculoskeletal
- Formes courantes
- injection
- Dosages courants
- 15 mg
- Interactions connues
- 9 (Modérée: 5 · Mineure: 4)
- Noms commerciaux
- 1
- Pays et marchés
- 1
Indications
Mécanisme d'action
Bisphosphonate which inhibits bone resorption via actions on osteoclast activity, leading to an indirect increase in bone density
Posologie adulte habituelle (résumé de la notice)
Hypercalcemia of Malignancy (Moderate hypercalcemia) (ie, corrected serum calcium 12-13.5 mg/dL): 60-90 mg single-dose IV infusion over 2-24 hours
Grossesse et allaitement
- Grossesse
- Unsafe No human data on fetal risk. Bisphosphonates enter bone and are released over years; in animals pamidronate caused bone mineralisation defects and embryo-fetal effects. UK label: do not use at any stage of pregnancy unless life-threatening hypercalcaemia cannot be controlled otherwise.
- Allaitement
- Unknown Very low milk levels after a 30 mg IV dose, and it is poorly absorbed by mouth. UK label: not recommended (possible bone effects); US: decide on nursing or the drug. LactMed: infant absorption unlikely; withholding feeds for 12-24 h after a dose minimises exposure.
Effets indésirables signalés
- Anemia
- Hypokalemia
- Urinary tract infectious disease
- Hypocalcemia
- Hypomagnesemia
- Hypophosphatemia
Contre-indications
- Hypersensitivity to drug, other bisphosphonates, or excipients, including mannitol
Précautions particulières
- Bisphosphonates, such as pamidronate disodium, have been associated with renal toxicity, including focal segmental glomerulosclerosis
Informez votre pharmacien ou votre médecin en cas de grossesse ou d'allaitement, de maladie rénale ou hépatique, d'allergies, ainsi que de tout autre médicament ou complément que vous prenez.
Principales interactions (9)
- Aluminum hydroxide + Pamidronate Moderate
- Dichlorphenamide + Pamidronate Moderate
- Foscarnet + Pamidronate Moderate
- Pamidronate + Tenofovir df Moderate
- Pamidronate + Tenofovir disoproxil Moderate
- Calcium + Pamidronate Minor
- Calcium carbonate + Pamidronate Minor
- Entecavir + Pamidronate Minor
- Pamidronate + Teriparatide Minor
Réservé aux membres Pro+
Débloquer la page complète
Créez un compte et lancez un essai Pro+ pour ouvrir la monographie complète de Pamidronate : posologie, grossesse et allaitement, effets indésirables, mises en garde et toutes les interactions.
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Pharmacokinetics
- Patient counselling points
- Food interactions
- IV preparation and dilution
Essayez Pro+ gratuitement pendant 7 jours sur le web. Sans carte.
Autres médicaments de cette classe
Questions fréquentes
What is Pamidronate used for?
Pamidronate is a medicine in the class musculoskeletal. It is used for Hypercalcemia of malignancy, Osteolytic bone lesions of MM, Osteolytic bone metastases of BC, Paget's disease.
What side effects have been reported with Pamidronate?
Anemia, Hypokalemia, Urinary tract infectious disease, Hypocalcemia, Hypomagnesemia, Hypophosphatemia.
Can Pamidronate be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. No human data on fetal risk. Bisphosphonates enter bone and are released over years; in animals pamidronate caused bone mineralisation defects and embryo-fetal effects. UK label: do not use at any stage of pregnancy unless life-threatening hypercalcaemia cannot be controlled otherwise. Breastfeeding: Unknown. Very low milk levels after a 30 mg IV dose, and it is poorly absorbed by mouth. UK label: not recommended (possible bone effects); US: decide on nursing or the drug. LactMed: infant absorption unlikely; withholding feeds for 12-24 h after a dose minimises exposure.
What does Pamidronate interact with?
MediHelp lists 9 known interactions for Pamidronate. Moderate: 5 · Minor: 4. The most serious include Aluminum hydroxide, Dichlorphenamide, Foscarnet.
Monographies complètes, posologies et vérificateur d'interactions dans l'application MediHelp
Ouvrez le référentiel complet, vérifiez les interactions entre plusieurs médicaments et utilisez les outils de posologie dans l'application MediHelp.
